Quick Takeaways
- This page summarizes David Mark McClung's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 29 Aug 2023, 16:15.
David Mark McClung - 25 Aug 2023 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)
- Signature
- David Mark McClung, by /s/ Ron A. Metzger, Attorney-in-Fact
- Issuer symbol
- SGMO
- Transactions as of
- 25 Aug 2023
- Net transactions value
- -$1,482
- Form type
- 4
- Filing time
- 29 Aug 2023, 16:15:12 UTC
- Previous filing
- 26 Jun 2023
- Next filing
- 28 Nov 2023
- SEC
- View on sec.gov
Quoteable Key Fact
"David Mark McClung filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 29 Aug 2023."
What Changed
- Previous filing in this sequence was filed on 26 Jun 2023.
- Current net transaction value: -$1,482.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SGMO | Common Stock | Tax liability | $1,482 | -1,925 | -0.89% | $0.7700 | 214,396 | 25 Aug 2023 | Direct | F1, F2, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on August 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on August 25, 2023 of $0.77/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise. |
| F2 | Includes: (a) 3,644 shares resulting from the August 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 33,413 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 13,336 shares subject to Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (d) 56,250 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
| F3 | Includes 5,000 shares acquired on May 31, 2023 under the Issuer's 2020 Employee Stock Purchase Plan. |